The investigation concerns whether Caribou and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On June 2, 2024, Caribou issued a press release announcing that the Company had "presented updated clinical data from the ongoing ANTLER Phase 1 trial that indicates a single dose of CB-010, a readily available, offthe-shelf anti-CD19 CAR-T cell therapy with a PD-1 knockout, has the potential to rival the safety, efficacy, and durability of approved a ...